Long-term Efficacy and Safety of Tamsulosin for Benign Prostatic Hyperplasia

Overview

Journal Rev Urol

Date 2006 Sep 21

PMID 16986054

Citations 11

Authors

Perinchery Narayan

Hari Siva Gurunadha Rao Tunuguntla

Affiliations

Soon will be listed here.

Abstract

The treatment approach for recent benign prostatic hyperplasia has changed since the recent introduction of medical therapies with evidence-based efficacy. The choice of treatment to achieve symptom relief must take into account factors such as clinical benefits, potential for morbidity, probable long-term efficacy, and costs. alpha(1)1-Adrenergic receptor antagonists are the primary therapy for patients with benign prostatic hyperplasia presenting with lower urinary tract symptoms and are used by 80% of physicians as the first-line agent to treat this common condition in the aging male. Tamsulosin has been available in the United States since 1997 and has demonstrated its efficacy. Of patients completing 6 years of treatment, 80.7% demonstrated consistent positive response with extremely low incidence of orthostasis, the response being greatest during the first year and largely maintained over the following 5 years.

Citing Articles

Orthostatic Hypotension in Benign Prostatic Hyperplasia Patients and Its Association With Alpha-1 Antagonist Use: A Comprehensive Literature Review.

Abubakar M, Prasad R, Salim S, Basavaraju D, Khan M, Lateef I Cureus. 2023; 15(8):e44097.

PMID: 37750139 PMC: 10518119. DOI: 10.7759/cureus.44097.

Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia.

Soliman M, Al-Ghadeer M, Al-Shabaan H, Al-Hamrani A, AlGhadeer H Urol Ann. 2023; 15(1):43-47.

PMID: 37006221 PMC: 10062509. DOI: 10.4103/ua.ua_143_21.

Are adrenergic α1- antagonists beneficial for the access of retrograde ureteral access sheath or semi-rigid ureteroscope access? A systematic review and meta-analysis.

Hu Q, Yuan C, Shen S, Jian Z, Jin X, Ma Y Front Surg. 2023; 9:1055904.

PMID: 36684219 PMC: 9849750. DOI: 10.3389/fsurg.2022.1055904.

Factors Affecting the Outcome of Medical Treatment in Cats with Obstructive Ureteral Stones Treated with Tamsulosin: 70 Cases (2018-2022).

Chae H, Hong H, Lee S, Park J, Choi W, Oh S Vet Sci. 2022; 9(10).

PMID: 36288181 PMC: 9608446. DOI: 10.3390/vetsci9100568.

Development and optimization of a tamsulosin nanostructured lipid carrier loaded with saw palmetto oil and pumpkin seed oil for treatment of benign prostatic hyperplasia.

Bakhaidar R, Hosny K, Mahier I, Rizq W, Safhi A, Bukhary D Drug Deliv. 2022; 29(1):2579-2591.

PMID: 35915055 PMC: 9477485. DOI: 10.1080/10717544.2022.2105448.

References

Schulman C, Cortvriend J, Jonas U, Lock T, VAAGE S, Speakman M . Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol. 1999; 36(6):609-20. DOI: 10.1159/000020056. View

Narayan P, Tewari A . A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol. 1998; 160(5):1701-6. View

Narayan P, Lepor H . Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology. 2001; 57(3):466-70. DOI: 10.1016/s0090-4295(00)01042-6. View

Schulman C, Lock T, Buzelin J, Boeminghaus F, Stephenson T, Talja M . Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol. 2001; 166(4):1358-63. View

Berry S, Coffey D, Walsh P, EWING L . The development of human benign prostatic hyperplasia with age. J Urol. 1984; 132(3):474-9. DOI: 10.1016/s0022-5347(17)49698-4. View

Lepor H . Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology. 1995; 45(3):406-13. DOI: 10.1016/s0090-4295(99)80008-9. View

Chute C, Panser L, Girman C, Oesterling J, Guess H, Jacobsen S . The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993; 150(1):85-9. DOI: 10.1016/s0022-5347(17)35405-8. View

Chapple C, Wyndaele J, Nordling J, Boeminghaus F, Ypma A, Abrams P . Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996; 29(2):155-67. View

Lepor H, Kaplan S, Klimberg I, Mobley D, Fawzy A, Gaffney M . Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol. 1997; 157(2):525-30. DOI: 10.1016/s0022-5347(01)65193-0. View

10.

Jacobsen S, Jacobson D, Girman C, Roberts R, Rhodes T, Guess H . Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997; 158(2):481-7. DOI: 10.1016/s0022-5347(01)64508-7. View

11.

Lowe F . Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther. 1997; 19(4):730-42. DOI: 10.1016/s0149-2918(97)80097-5. View

12.

McConnell J, Bruskewitz R, Walsh P, Andriole G, Lieber M, HOLTGREWE H . The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998; 338(9):557-63. DOI: 10.1056/NEJM199802263380901. View

13.

Lepor H . Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998; 51(6):892-900. DOI: 10.1016/s0090-4295(98)00126-5. View

14.

Lepor H . Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 1998; 51(6):901-6. DOI: 10.1016/s0090-4295(98)00127-7. View

15.

Andriole G, Guess H, Epstein J, Wise H, Kadmon D, Crawford E . Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998; 52(2):195-201; discussion 201-2. DOI: 10.1016/s0090-4295(98)00184-8. View

16.

Roehrborn C, Bruskewitz R, Nickel G, GLICKMAN S, Cox C, Anderson R . Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. Eur Urol. 2000; 37(5):528-36. DOI: 10.1159/000020189. View